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).Summary
Dry powder devices are rarely used in the emergency room (ER) treatment of acute and
severe bronchoconstriction due to hesitations with respect to clinical efficacy.
This study investigated the effects of two inhalers with formoterol in patients visiting the
ER Department for acute and severe dyspnoea, mainly exacerbations of chronic
obstructive pulmonary disease. Two doses of 12 mg formoterol were given at enrolment,
either via Turbuhaler or via pressurised metered dose inhaler, connected to a spacer device
(pMDI+S) in a double-blind way and parallel design. Another two doses of 12 mg formoterol
were given after 30min. Forced expiratory volume in the 1 s (FEV1) and Borg dyspnoea
score were assessed until 60min. The study was designed to test non-inferiority in effects
on FEV1. Seventy-seven patients were enrolled with a mean age of 66 years and a FEV1
of 1.03 L (39% of predicted). The effects of the two treatments were almost identical.
The mean improvement in FEV1 at 60min after formoterol Turbuhaler was 94% of the
improvement after formoterol pMDI+S. A statistically significant non-inferiority was shown
(p ¼ 0.037) at 60min (primary endpoint) as well as at 5 and 30min (secondary endpoints,
p ¼ 0.0043 and 0.013, respectively). Improvements in the Borg dyspnoea score and other
lung-function parameters did not differ significantly between the two devices.
In conclusion, formoterol Turbuhaler was equally effective as formoterol pMDI+S in the
treatment of acute bronchoconstriction within the ER.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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ziekenhuis.nlIntroduction
Patients with obstructive airway diseases, such as asthma
and chronic obstructive pulmonary disease (COPD) may
experience episodes of bronchoconstriction, leading to
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a frequent cause for unscheduled visits to health care
professionals and emergency rooms (ERs).1,2
The current practice in the treatment of patients with
severe acute exacerbations of asthma and COPD within the
ER, is to administer high doses of a b-2 agonist either by
nebulisation or by a pressurised metered dose inhaler,
connected with a large volume spacer device (pMDI+S).2
The use of a dry powder inhaler device is assumed to be less
effective in these patients due to the assumed reduced
inspiratory flow through the inhaler, which is necessary to
inhale adequately.3 However, in asthmatic patients, even in
an acute and severe airway obstruction, inhalation via
Turbuhaler has been proven to be as effective as inhalation
via a pMDI+S.4,5 No such studies are available in the initial ER
treatment of patients with severe exacerbations of COPD.
Nevertheless, patients with stable COPD and patients with
an acute and severe asthma exacerbation were able to
generate a peak inspiratory flow (PIF) through the Turbu-
haler, which would theoretically allow an efficient disin-
tegration of drug particles from this device during
inhalation.6,7
Formoterol is a b-2 agonist with a rapid onset of action,
comparable to that of the traditional short-acting bronch-
odilators8,9 but it also has a long duration of effect.10 Recent
studies showed the inhaled formoterol Turbuhaler to be
more effective than both terbutaline and salbutamol when
used ‘‘as needed’’ in both asthma and COPD.11–14 While
formoterol Turbuhaler was used successfully in situations of
acute dyspnoea in asthma,8 and in episodes of induced
moderate bronchoconstriction in COPD,15 its use has not
been investigated in episodes of severe bronchoconstriction
in COPD, which would be required to fully trust the use of
Turbuhaler under all circumstances.
The main research question of the present study was to
test non-inferiority of the clinical effect of inhalation of
formoterol Turbuhaler in comparison with formoterol in-
haled via pMDI+S, in patients with severe dyspnoea visiting
the ER. In our hospital, this category consists mainly of
patients with an exacerbation of COPD.Methods
Patients
Patients with acute and severe dyspnoea, presumed to be
due to an exacerbation of obstructive airway disease, were
asked to participate in this study, while presenting with an
unscheduled visit, mainly at the ER and some in the
outpatient clinic. Before entering the study the arterial
blood gas values were assessed and an ECG and chest X-ray
were taken, so that other causes of dyspnoea such as
pneumoniae or cardiac failure were ruled out.
The most important inclusion criteria were an age above
18 years and a forced expiratory volume in 1 s (FEV1) of
o70% of that predicted16 but more than 0.5 L. The diagnosis
of obstructive airway diseases had to be present for at least
6 months, either confirmed by a general practitioner or by a
pulmonologist. Excluded were patients with a known
hypersensitivity to inhaled formoterol and those patientswith significant concomitant diseases or conditions and
those requiring immediate ventilator support.
At a later stage, after commencing the treatment, each
patient’s medical record was checked in depth and the
patient was assigned to the prior defined subgroup of
‘‘confirmed diagnosis of COPD’’ if age was445, no history of
concomitant or previous asthma was found, a smoking
history of more than 15 pack years was documented and the
postbronchodilator FEV1/FVC (forced vital capacity) ratio
(determined in a stable situation for the past twelve
months) was less than 0.70. All subjects gave written
informed consent and the study was approved by the
Medical Ethics Committee. A preliminary written informed
consent was obtained upon arrival at the ER. A full-length
written informed consent was obtained within 2 h after
enrolment.
Study design
The study had a double-blind, randomised, parallel-group
design using double dummy technique and was performed in
a non-university teaching hospital. The study personnel, the
pharmacist, the data-management personnel and the study
monitor were blinded until ‘‘clean file’’ was declared and
the code was broken. To ensure optimal care, the study was
performed only during daytime shifts. After the diagnosis
‘‘acute and severe dyspnoea, likely to be due to an
exacerbation of an obstructive airway disease’’ was made,
other causes for dyspnoea were excluded and informed
consent was obtained. The inhalation technique was briefly
checked and when necessary corrected by the study
personnel to ensure a correct inhalation technique. After
assessing the baseline measurements of lung function and
Borg dyspnoea score, the first dose of 24 mg formoterol (as 2
doses of 12 mg) was administered under supervision of the
study personnel and the time was set at 0min. Randomisa-
tion of study treatments was performed by a computer
program. For each patient there was a package with one
Turbuhaler and one pMDI plus spacer, one containing active
medication and the other inhaler containing placebo.
Each patient received active formoterol, either via
Turbuhaler (Oxiss Turbuhalers, 12 mg per metered dose,
equivalent with 9 mg delivered dose, AstraZeneca, Sweden)
or via pMDI (Foradils CFC metered dose inhaler, 12 mg per
metered dose, Novartis, Switzerland) connected to a spacer
device (Aerochambers, Boehringer Ingelheim, Germany)
and a placebo via the other device. The two pMDI’s and
Turbuhalers had identical appearances. Half of the patients
inhaled first from Turbuhaler, the other half first from
pMDI+S. At 30min, a second dose of two inhalations of 12 mg
formoterol was given. For ethical reasons no placebo was
included. Lung function and dyspnoea score were assessed
at baseline and at 5, 15, 30 (prior to the second dose of
formoterol), 45 and 60min.
Measurements
Patients performed three acceptable forced expiratory
measurements at all time points (portable spirometer
Vitalograph 2120 and Jeager masterscreen), recorded sitting
in an upright position and wearing a nose-clip. Three lung
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mean forced expiratory flow between 25% and 75% of FVC
(FEF25–75). At enrolment PIF was additionally measured. The
highest values were recorded, whether or not from the same
attempt. The predicted values of FEV1 were calculated
according to the ERS specification.16 After each lung
function measurement, the patients were asked to score
their dyspnoea on the Borg scale which ranges from 0
( ¼ none) to 10 ( ¼ extreme).17 At baseline and after
60min, blood pressure and pulse rate were measured.
During the 1 h study period no concomitant bronchodilatat-
ing therapy was given. Patients received oxygen, corticos-
teroids and antibiotics when needed. Administration of
additional bronchodilator treatment in the first hour after
the study-drug administration was allowed, but would be
regarded as ‘‘treatment failure’’ and would lead to with-
drawal from the study.Data analysis
The primary analysis was aimed at investigating non-
inferiority in effects on FEV1. Treatment via the new
treatment (Turbuhaler) was regarded to be non-inferior to
the standard treatment (pMDI+S), when the mean increase
in FEV1 within the Turbuhaler group at 60min including its
lower one-sided 95% confidence interval (C.I.) would be
greater than 85% of the mean increase in FEV1 within the
pMDI+S group. This 95% C.I. and the level of 85% were chosen
in line with European guidelines on non-inferiority and were
more demanding than the 80–125% limits usually required
for bio-equivalence.18 Non-inferiority was tested statisti-
cally for the change in FEV1 at 60min (the primary
parameter) and at 5 and 30min. Secondary analyses were
focussed on investigating the potential differences between
treatments for the changes in FEV1, FVC, FEF25–75 and the
Borg score at a limited series of time points and for the areas
under the curve (AUC) over the entire 60min interval
(AUC060) for FEV1, FVC, FEF25–75 and the Borg score.
The statistical analysis was performed by analysis of
variance (ANOVA) using a multiplicative model with the
factor treatment, and the log-transformed baseline FEV1 asTable 1 Demographic and baseline data.
Turbuhaler
Male/female 25/14
Age (year) 67.1713.3
‘‘Confirmed diagnosis of COPD’’ (yes/no) 25/14
No/ex/current smoker 4/22/13
Pack years (only ex/current smokers) 30 (1–120)
BMI (kg/m2) 2776
FEV1 (L) 0.9870.34
FEV1 (% of predicted) 38.3712.6
Borg score 5 (1–10)
PIF (L/min) 1967137
Data as mean7SD, except for Pack years and Borg score: median (ra
pMDI+S: pressurised metered dose inhaler connected to a spacer; BMI
peak inspiratory flow.percentage predicted as a covariate. Lung function data are
expressed and analysed as the ratio at each time point
relative to the value at 0min and as the ratio of the effects
Turbuhaler/pMDI+S. The least-squared means resulting from
this model were used to calculate the one-sided 95%
confidence interval for the log-transformed difference
between the treatments: log(Turbuhaler) minus log(pMDI+S).
These data were back-transformed to geometric means and
its C.I. For the AUC060 and Borg data an additive ANOVA was
used. Data of all patients were used in the statistical
analysis but results are described separately for the
subgroup of ‘‘confirmed diagnosis of COPD’’, though without
statistical comparison between treatments. The Pearson’s
correlation coefficient was calculated for the relation
between PIF and the treatment effect on FEV1 within the
two treatment groups. Assuming an actual effect of
Turbuhaler relative to pMDI+S of 495%, 37 patients were
calculated to be needed in each group in order to state non-
inferiority with an alpha of 5% and a power of 80%.Results
Patients
In total, 77 patients were enrolled and randomised in the
period of June 2003–May 2005: 39 received treatment via
Turbuhaler and 38 via pMDI+S. Two patients were withdrawn
from the study, one because the FEV1 was higher than
allowed (more than 70% of predicted) and one patient due to
malfunctioning of the spirometer. Demographic and baseline
data of the two groups are shown in Table 1.
Patients were predominantly elderly men with a mean
age of 66 years, having a significant smoking history of 32
pack years. At enrolment, 52 patients used inhaled
corticosteroids, 61 patients a long-acting-b-2-agonist, 22
patients a long-acting anticholinergic agent and 12 patients
were on oral theophylline. An oral corticosteroid course was
started by the general practioner in 22 patients in the last
days prior to enrolment to this study. Medication use was
similar in the two treatment groups.pMDI+S Total
26/12 51/26
65.3710.8 66.2712.1
24/14 49/28
1/24/13 5/46/26
33 (1–133) 32 (1–133)
2775 2776
1.0970.46 1.0370.40
40.3717.8 39.3715.3
5 (1–9) 5 (1–10)
2187155 2077145
nge).
: body mass index; FEV1: forced expiratory volume in the 1 s; PIF:
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Score 5) and FEV1 was 1.03 L, equivalent to 39% of
predicted. Forty-nine patients (64%) were eventually classi-
fied as having a ‘‘confirmed diagnosis of COPD’’, 25 in the
Turbuhaler group and 24 in the pMDI+S group. Lack of
available lung-function data in the previous 12 months in
a stable state and a smoking history of 10–15 pack years
were the most common reasons (23 patients) to fail for
classification for the ‘‘confirmed diagnosis of COPD’’. After
the study, five patients were later characterised as having
primarily asthma by the pulmonologist.
The two treatment groups were comparable, except that
the patients randomised to treatment via Turbuhaler were
on average 2 years older and had at enrolment a 10% lower
FEV1 and a 10% lower PIF. Thirty-five patients were
hospitalised after completion of the 1 h observation period
(18 after Turbuhaler treatment and 17 after pMDI+S). None
were admitted to medium or intensive care. None of the
patients required additional bronchodilator therapy during
the 1 h observation period, which would be classified as
treatment failure.Figure 1 Mean increase in FEV1 (SEM) for 60min after treatment
with formoterol, inhaled via Turbuhaler (squares) or pressurised
metered dose inhaler with Spacer (pMDI, triangles) in patient with
acute dyspnoea. (A) all patients (n ¼ 77, filled symbols) and (B)
‘‘confirmed diagnosis of COPD’’ (n ¼ 49, open symbols).Outcome measures
From enrolment, FEV1 increased significantly and almost
identically under both treatments. At 60min the mean FEV1
was 14.1% above the baseline in the group treated with
formoterol via Turbuhaler and 20.0% in the group treated via
the pMDI+S. After correction for differences in baseline, the
relative effect of formoterol via Turbuhaler was 94% of the
effect of formoterol via pMDI, theTurbuhaler/pMDI+S at
60min became 0.94 with a lower limit of the one-sided 95%
C.I. of 0.86 (p ¼ 0.037), hereby showing treatment via
Turbuhaler to be statistically significant ‘‘non-inferior’’ to
the pMDI+S.
Within the group of 49 patients with ‘‘confirmed diagnosis
of COPD’’ the ratio Turbuhaler/pMDI+S was 0.98 (95% C.I. of
0.87–1.07). Results are depicted in Figure 1A (all patients)
and B (‘‘confirmed diagnosis of COPD’’ patients). Similar,
non-inferiority was shown at 5min (ratio 0.94, p ¼ 0.0043,
within the ‘‘confirmed diagnosis of COPD’’ subgroup the
ratio was 0.98) and at 30min (ratio 0.96, p ¼ 0.013, within
the ‘‘confirmed diagnosis of COPD’’subgroup the ratio
was 1.03).
The two treatments also induced similar effects in FVC
and FEF25–75. Results are shown in Table 2. At all tested time
points the differences in treatment via Turbuhaler were
shown to be non-significant compared to treatment via
pMDI+S.
The three lung-function parameters were also analysed as
AUC from 0 to 60min. Both for FEV1 and FVC the AUC values
were not statistically significant different (p ¼ 0.072 and
0.19, respectively), but for FEF25–75, the AUC was signifi-
cantly larger for the pMDI+S (p ¼ 0.044).
Within 5min after inhalation, the Borg score decreased in
both treatment groups (Figure 2). The decrease in both,
within the total study population and within the ‘‘confirmed
diagnosis of COPD’’ subgroup was numerically larger after
treatment via Turbuhaler, compared to pMDI+S, but the
differences were not statistically significant. The AUC valuesfor the Borg score were not significantly different
(p ¼ 0.28).
PIF at enrolment was on an average 207 L/min. The value
of PIF did not show a significant correlation with the
treatment effect (% increase in FEV1 at 60min), neither
within the pMDI+S group (r ¼ 0.08, p ¼ 0.68) nor within
the Turbuhaler group (r ¼ 0.15, p ¼ 0.44). These results
are shown in Figure. 3.
No treatment failures were noted, which were defined as
the requirement of additional bronchodilator medication.
Four patients, all in the pMDI group, experienced an adverse
event (increased blood pressure in two patients, and chills
and rales each in one patient). No serious adverse events
occurred in the study.
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Table 2 Relative effects of formoterol via Turbuhaler and via pMDI+S on lung function and Borg score.
Turbuhaler
all patients
PMDI+S
all patients
Turbuhaler
‘‘confirmed
diagnosis of
COPD’’
PMDI+S
‘‘confirmed
diagnosis of
COPD’’
p-Value for
non-inferiority,
all patients
p-Value for
difference,
all patients
FEV1 at 5min 1.0970.13 1.1370.11 1.0870.18 1.0870.13 0.004 0.080
FEV1 at 30min 1.1270.19 1.1370.17 1.1270.22 1.0970.13 0.013 0.48
FEV1 at 60min
 1.1470.19 1.2070.20 1.1270.20 1.1570.15 0.037 0.29
FEF2575 30min 1.0770.30 1.1470.29 1.1170.30 1.0670.28 n.t. 0.055
FEF25–75 60min 1.0670.30 1.2470.45 1.0570.25 1.1670.45 n.t. n.t.
FVC at 60min 1.1270.15 1.1570.24 1.1570.17 1.1370.24 n.t. 0.41
Borg at 5min 0.5871.08 0.4370.92 0.6471.22 0.3370.73 n.t. 0.92
Borg at 30min 1.1771.53 0.6871.32 1.0071.53 0.4670.96 n.t 0.15
Borg at 60min 1.3871.67 0.8571.51 1.2071.58 0.6371.17 n.t. n.t.
Data on 77 patients (mean7SD) randomised to treatment via Turbuhaler (n ¼ 39) or pressurised metered dose inhaler with spacer
(pMDI+S) (n ¼ 38). Data is expressed as changes from the values at 0min, for lung function as the ratio and for the Borg score as the
decrease from the data at 0min.
FEV1: forced expiratory volume in the first second; FVC: forced vital capacity; FEF25–75: forced expiratory flow between 25% and 75% of
FVC; n.t: not tested; no statistical comparison within the subgroup with ‘‘confirmed diagnosis of COPD’’ was foreseen.
Primary parameter; ‘‘confirmed diagnosis of COPD’’, see text.
Formoterol Turbuhaler in acute dyspnoea 583Discussion
The present study was performed to investigate the relative
efficacy of formoterol, inhaled via either Turbuhaler or
pMDI+S in patients with severe dyspnoea due to obstructive
airway diseases, treated in an ER Department in a double-
blind, randomised, parallel-group design using double
dummy technique. In these patients, a statistically signifi-
cant non-inferiority of the Turbuhaler was shown, compared
to a generally accepted method of administration of
bronchodilators via pMDI+S. Almost identical effects were
observed after inhaling the same dose through the two
different inhalers for three objective parameters of lung
function and for the subjective parameter dyspnoea,
indicating that Turbuhaler was genuine and equally effective
as the pMDI+S under these demanding circumstances of
severe dyspnoea and bronchoconstriction. The effect on
FEV1 after inhaling formoterol through Turbuhaler at 5, 30
and 60min was 94%, 96% and 94%, respectively, of the effect
after inhaling through pMDI+S. The similarity in the clinical
effect after the use of the two different devices indicates
that the amount of formoterol reaching the lungs from the
two different devices is similar.19 Patients were treated
immediately upon arrival, as deemed necessary for ethical
reasons. The precise diagnosis and historical lung function
data, obtained in a stable phase in the previous 6 months,
were established later and indicated that the majority of
patients had exacerbations on top of a moderate to severe
COPD. None of the patients required additional bronchodi-
lating treatment during the 1 h observation period, which
would indicate treatment failure, and a similar proportion of
patients were hospitalised after the 1 h study for further
(corticosteroid) treatment.
Both the onset of the effect and the magnitude of the
effect, assessed via the various lung function parameters,
measured in this study, were similar on all time points in the
two treatment groups. For obvious reasons no placebotreatment group was incorporated in the present study and
thus the absolute effect of inhaled formoterol in the present
patient population cannot be assessed. A relatively low dose
of only two inhalations of 12 mg was administered at
enrolment, leading to similar bronchodilating effects im-
mediately 5min after inhalation, making it unlikely that lack
of differences was caused by administering supra-maximal
doses. The relative effects in the two treatment groups
were so similar that missing a clinically relevant difference
in effect is very unlikely.
It has been suggested that the effective use of a dry
powder device is impossible in patients with a low-
inspiratory flow, e.g. patients with an exacerbation of
COPD.3 The results from the present study do not confirm
this hypothesis. However, because of differences in the dry
powder inhaler characteristics, one should be cautious to
extrapolate this finding to all other dry-powder inhalers. It
may be concluded however, that inspiratory flow is not as
reduced as expiratory flow. Our present findings are in line
with the earlier studies which showed that Turbuhaler can
be used effectively in patients with an exacerbation of their
asthma,4,5,8 and those of Dewar et al.6 who showed that
patients with severe COPD can create a PIF which is
theoretically high enough to use Turbuhaler efficiently.
The rapid effects on lung function and dyspnoea confirm the
findings of Maessen et al.20 and Cazzola et al.21 in patients
with severe but stable COPD allowing study designs with
assessments on subsequent test days. A recent study
investigating lung deposition of formoterol Turbuhaler in
patients with moderate-to-severe COPD showed that lung
deposition was not related to the expiratory-flow lung
function parameters.22
The two treatment groups were comparable, except that
the patients randomised to treatment via Turbuhaler were
older and had a more severe disease, as shown from a 10%
lower FEV1 and PIF. This could have favoured the pMDI+S
group, since older patients and those with a more severe
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Figure 2 Mean decrease in Borg dyspnoea score (SEM) for
60min after treatment with formoterol, inhaled via Turbuhaler
(squares) or pressurised metered dose inhaler with Spacer
(pMDI, triangles) in patient with acute dyspnoea. (A) all patients
(n ¼ 77, filled symbols) and (B) ‘‘confirmed diagnosis of COPD’’
(n ¼ 49, open symbols).
Figure 3 Relation between peak inspiratory flow (PIF) at
enrolment and clinical effect on FEV1 at 60min after inhalation
of 2 24mg formoterol via Turbuhaler (filled squares) or
pressurised metered dose inhaler connected to a Spacer (open
triangles).
K.M. van den Broek et al.584COPD may be expected to show the smallest reversibility,
but it seems unlikely that these differences influence the
outcome of the study. Additionally, baseline lung function
was used as the covariate in the statistical analyses.
The AUC of the FEF25–75 was significantly larger in the
pMDI+S group, mainly due to one person with an extreme
positive reaction after formoterol inhalation, who was later
diagnosed as having primarily asthma.
Interestingly, the changes in the Borg score, both in the
‘‘confirmed diagnosis of COPD’’ and in the total study
population were numerically larger (almost two-fold) after
inhalation via Turbuhaler compared to inhalation via
pMDI+S. Though the study was performed with the double
dummy technique and placebo inhalers, this may indicate
that a sensed inhalation is not a requirement for a
subjective effect.In conclusion, our study is to present knowledge the first
study, examining the use of a dry powder inhaler (such as the
Turbuhaler) in patients visiting the ER Department with
acute and severe dyspnoea due to an exacerbation of
obstructive airways. It was shown that the Turbuhaler was
an equally effective inhaler as the pMDI+S in delivering the
bronchodilator formoterol, even in the ‘‘confirmed diagnosis
of COPD’’ subgroup. These results give confidence for
patients using the Turbuhaler as a rescue medication, even
in these circumstances.4,5,14,23Acknowledgements
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